MedTrace Logo

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

NCT03289533 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-09-04

Study results available
· View outcomes & findings →

Summary

To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Avelumab (MSB0010718C)

Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.

DRUG

Axitinib (AG-013736)

Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-08
Primary Completion
2019-08-27
Completion
2019-10-25

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03289533 on ClinicalTrials.gov